The Quantellect read.As of Nov 19, 2026, 7 active firms cover Sotera Health Co: 6 rate it Buy or better, 0 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. Targets span $17.00 to $25.00, a moderate spread. The average target of $22.17 sits 36% above the current $16.27. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.20 next quarter toward $1.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy686%
Neutral00%
Sell114%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$22.17
+36.2% upside
Average target across 6 active firms as of Nov 19, 2026 vs $16.27 current
Highest Target$25.00
Average Target$22.17
Lowest Target$17.00
Detailed analyst forecasts for SHC
Showing 1–8 of 8 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 6 of 7 active firms rate SHC a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SHC EPS & revenue forecast
EPS · NEXT QUARTER
$0.20
Range $0.18 – $0.22 · 8 analysts · +11% YoY
Next period, 8 analysts expect Sotera Health Co to earn $0.20 a share (range $0.18 – $0.22), versus $0.18 a year earlier. Full-year consensus is $0.98, growing to $1.07 the year after.
REVENUE · NEXT QUARTER
$294.3M
Range $292.7M – $296.3M · 8 analysts · +5% YoY
Revenue is expected to reach $294.3M (range $292.7M – $296.3M), +5.1% year-over-year. Full-year consensus is $1.2B, rising to $1.3B next year.
Top analysts covering Sotera Health Co
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SHC.
#1
Luke Sergott
Barclays · Rank #267
Buy
$22.00+35.2% to target
Overall win rate
43%
+ Follow
#2
Matthew Sykes
Goldman Sachs · Rank #352
Buy
$17.00+4.5% to target
Overall win rate
38%
+ Follow
#3
Jason Bednar
Piper Sandler · Rank #360
Buy
$25.00+53.7% to target
Overall win rate
33%
+ Follow
#4
Patrick Donnelly
Citigroup · Rank #448
Buy
$23.00+41.4% to target
Overall win rate
29%
+ Follow
#5
CW
Casey Woodring
JP Morgan
Sell
$17.00+4.5% to target
Coverage
—
+ Follow
SHC stock forecast FAQ
What is SHC's average 12-month price target?+
The 6 active firms with a live target average $22.17 for Sotera Health Co over the next 12 months, ranging from a $25.00 high to a $17.00 low, as of Nov 19, 2026.
Is SHC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SHC?+
The Street-high target is $25.00 (Citigroup), and the Street-low is $17.00 (JP Morgan). The average of all 6 active-firm targets is $22.17.
How many active Wall Street firms cover SHC?+
7 active firms have a recognized rating on Sotera Health Co as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SHC?+
Among analysts who currently cover SHC, Luke Sergott of Barclays has the strongest overall Quantellect track record (Rank #267). Their current call is Buy with a $22.00 target.
What is Sotera Health Co's projected EPS for next quarter?+
The consensus estimate is $0.20 per share (range $0.18 – $0.22) across 8 analysts. Full-year EPS is projected at $0.98, rising to $1.07 the following year.
How much revenue is Sotera Health Co expected to report next quarter?+
Consensus revenue is $294.3M (range $292.7M – $296.3M). Full-year revenue is projected at $1.2B, growing to $1.3B next year.
Have analysts been upgrading or downgrading SHC lately?+
As of Nov 19, 2026, 6 of 7 active firms rate SHC a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SHC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.